Highlights Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
9.93 ^USD	-2.84%		+17.38%	-1.29%

02/05	Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
02/05	Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M	03/05	MT
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	05/03	CI
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	23/02	MT
Vir Biotechnology, GSK Terminate Collaboration on Flu	23/02	DJ
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M	23/02	MT
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA	23/02	CI
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	23/02	CI
Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q3 Revenue $2.6M, vs. Street Est of $8.8M	03/11	MT
Vir Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD?s the Liver Meeting® 2023	11/23/11	CI
Vir Biotechnology Gets $50 Million in US Government Funding to Support Antibody Platform Technologies Development	03/23/03	MT
Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV	20/23/20	CI
Vir Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04	CI
Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q2 Revenue $3.8M, vs. Street Est of $22.4M	04/23/04	MT
Vir Biotechnology, Inc. Announces Topline Data from Phase 2 Peninsula Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness	20/23/20	CI
Vir Biotechnology, Inc. and VBI Vaccines Inc. Present Results from Multiple Clinical Studies for the Treatment and Prevention of Chronic Hepatitis B Viral Infection at the European Association for the Study of the Liver Congress 2023	25/23/25	CI
Vir Biotechnology, Inc. Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D	24/23/24	CI
Vir Biotechnology, Inc. Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNa and an NRTI	11/23/11	CI
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $63M	05/23/05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Highlights

Filters